USA flag logo/image

An Official Website of the United States Government

High-throughput Epitope Mapping of Anti-Viral Antibodies

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43AI096936
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-050
Small Business Information
INTEGRAL MOLECULAR
3711 MARKET ST Suite 900 PHILADELPHIA, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: High-throughput Epitope Mapping of Anti-Viral Antibodies
Agency: HHS
Contract: 1R43AI096936-01
Award Amount: $242,376.00
 

Abstract:

DESCRIPTION (provided by applicant): The identification of highly potent and broadly neutralizing antibodies isolated from HIV-1- infected donors suggests that when presented with a suitable antigenic structure, the human immune system can produce protective antibodies that HIV-1 is unable to evade. Understanding these antigenic structures is a primary objective in developing a vaccine capable of generating broadly protective humoral immunity. Most of these broadly neutralizing MAbs bind conformationally complex epitopes on Envelope that have been difficult to epitope map, and an increasing number of such MAbs are being identified using more efficient approaches to MAb isolation. However, the ability to characterize MAbs has not kept up, leaving a major gapbetween the growing ability to isolate relevant MAbs and the ability to molecularly define the immunogenic structures that gave rise to them. The goal of this proposal is to develop tools to rapidly and comprehensively map MAb epitopes on structurally complex viral Envelope proteins. Identifying the epitopes of potent and broadly neutralizing MAbs will enable Env variants exhibiting improved antigenic characteristics to be more rapidly designed and tested as vaccine candidates. PUBLIC HEALTH RELEVANCE: This project will contribute to human health by identifying the epitopes of potent and broadly neutralizing MAbs so that Env variants exhibiting improved antigenic characteristics can be more rapidly designed and tested as vaccine candidates.

Principal Investigator:

Benjamin J. Doranz
215-966-6018
bdoranz@integralmolecular.com

Business Contact:

Benjamin Doranx
215-966-6018
bdoranz@integralmolecular.com
Small Business Information at Submission:

INTEGRAL MOLECULAR
3711 MARKET ST Suite 900 PHILADELPHIA, PA -

EIN/Tax ID: 123309196
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No